68

Guangzhou LBP Medicine Science & Technology Co Ltd

688393 · SHG · Healthcare / Medical Instruments & Supplies

17.67CNY-0.60 (-3.28%)

Price History

Full chart

Market Stats

Previous Close18.27
Open18.34
Day Range17.62 – 18.54
52-Week Range15.70 – 38.78
Volume1.64M
Market Cap2.10B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.36
Dividend Yield0.45%
Beta0.49
50-Day Avg20.10
200-Day Avg22.97

About

Guangzhou LBP Medicine Science & Technology Co., Ltd. engages in the research, development, and production of pathological diagnosis products in China and internationally. The company offers pathological diagnostic reagents and ancillary equipment that consists of liquid-based cytology products, including liquid-based cytology production machines and automatic sample transfer machines; polymerase chain reaction products, such as human papillomavirus gene test kits, sample preservation solutions, and automatic nucleic acid molecular hybridization instruments; fluorescence in situ hybridization products comprising auto-fish instruments, and AML1/ETO, EGFR, BCR/ABL fusion, PML/RARA, and TOP2A gene testing kits; and digital pathology products pathological medical image analysis processing systems, real-time microscopic visual field sharing systems, and bingli scanner. It also provides immunohistochemistry products including automatic antigen repair instrument and automatic immunocytochemical staining machine, as well as conversional pathology equipment. The company's products have applications in tumor screening, tumor subtyping, companion diagnostics, efficacy monitoring, and recurrence detection. It serves public hospitals, medical institutions, and pharmaceutical companies. Guangzhou LBP Medicine Science & Technology Co., Ltd. was founded in 2005 and is based in Guangzhou, China.

Company Details

  • SectorHealthcare
  • IndustryMedical Instruments & Supplies
  • CEOMr. Xiangting Cai
  • Employees790
  • HeadquartersNo. 2, Kexin Street, Guangzhou, China, 510663, China
  • Websitehttps://www.gzlbp.com

Leadership

  • Mr. Xiangting CaiChairman of the Board & GM · b. 1964
  • Mr. Quanneng HouCFO & Board Secretary · b. 1983
  • Aiping HuangAccounting Supervisor
  • Sun HuaDeputy GM & Director · b. 1973

Financials

Income Statement

Currency: CNY2011-12-312012-12-312013-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue87.72M107.45M142.60M241.16M260.47M306.30M355.16M375.43M438.99M507.38M497.29M470.79M347.27M
Growth (%)-+22.49%+32.72%+69.12%+8.01%+17.59%+15.95%+5.71%+16.93%+15.58%-1.99%-5.33%-26.24%
Cost of Revenue30.77M37.43M46.27M42.75M43.94M52.42M58.41M76.19M98.60M148.97M161.87M159.61M125.22M
Gross Profit56.95M70.02M96.33M198.41M216.53M253.87M296.75M299.24M340.39M358.41M335.42M311.18M347.27M
Gross Margin64.93%65.16%67.55%82.27%83.13%82.89%83.55%79.71%77.54%70.64%67.45%66.10%100.00%
Operating Expense29.61M41.05M56.07M151.43M155.88M179.51M207.95M199.05M251.45M329.73M313.91M300.18M399.18M
Operating Income27.34M28.97M40.26M46.98M60.65M74.36M88.80M100.20M88.94M28.68M21.51M11.00M-51.91M
Operating Margin31.17%26.96%28.23%19.48%23.28%24.28%25.00%26.69%20.26%5.65%4.33%2.34%-14.95%
EBITDA30.99M35.25M49.19M67.35M73.22M86.89M98.69M110.39M105.63M62.50M55.86M48.53M-17.79M
EBITDA Margin35.32%32.81%34.50%27.93%28.11%28.37%27.79%29.40%24.06%12.32%11.23%10.31%-5.12%
Net Income27.15M27.73M38.43M46.03M48.34M61.47M73.99M84.75M79.78M42.69M40.06M21.29M-44.97M
Net Income Margin30.95%25.81%26.95%19.09%18.56%20.07%20.83%22.57%18.17%8.41%8.06%4.52%-12.95%
R&D-15.98M10.62M13.25M15.30M15.59M21.86M27.73M45.90M67.39M62.69M45.47M36.06M
R&D as % of Total Revenue-14.87%7.45%5.49%5.88%5.09%6.15%7.39%10.46%13.28%12.61%9.66%10.38%
Interest Expense130.10K--40.60K48.08K18.00K113.44K73.77K524.99K1.36M808.03K854.87K327.03K
Interest Expense % of Total Revenue0.15%--0.02%0.02%0.01%0.03%0.02%0.12%0.27%0.16%0.18%0.09%

Balance Sheet

Currency: CNY2011-12-312012-12-312013-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets111.40M191.92M257.13M357.02M412.06M476.56M537.96M1.29B1.37B1.39B1.40B1.36B1.29B
Total Liabilities63.31M18.60M42.13M36.08M65.78M87.25M93.33M124.67M155.96M170.45M161.63M130.99M127.98M
Total Equity48.09M173.32M211.75M315.48M342.82M386.79M443.28M1.17B1.20B1.23B1.26B1.26B1.18B
Cash22.25M53.16M30.93M96.12M73.73M74.96M85.70M635.27M217.68M90.91M67.68M95.15M31.27M
Total Debt--10.28M----1.77M12.39M24.80M31.83M8.95M-
Net Debt-22.25M-53.16M-20.65M-96.12M-73.73M-74.96M-85.70M-633.50M-205.28M-66.11M-35.85M-86.20M-

Cash Flow

Currency: CNY2011-12-312012-12-312013-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-15.24M4.84M-696.70K43.37M83.92M65.35M89.74M91.43M59.61M9.72M17.12M3.54M40.02M
Investing Cash Flow-7.03M-42.13M-31.64M-22.32M-81.75M-46.98M-59.78M-183.31M-446.61M-114.92M-32.70M57.12M-
Financing Cash Flow29.54M68.20M10.10M-15.80M-24.40M-17.13M-19.22M639.33M-29.53M-21.40M-6.89M-34.72M-
Capital Expenditure5.95M15.25M54.70M15.79M33.43M43.92M35.54M62.45M143.34M72.17M37.74M23.65M23.15M
Free Cash Flow-21.20M-10.41M-55.40M27.59M50.49M21.43M54.20M28.98M-83.73M-62.45M-20.62M-20.10M16.87M
Dividends Paid-48.70K174.80K9.80M21.00M16.52M17.50M-26.14M25.20M13.47M14.51M9.53M
FCF to OCF139.06%-215.26%7951.72%63.60%60.16%32.79%60.39%31.70%-140.45%-642.74%-120.45%-567.35%42.15%
Dividend Paid to FCF--0.47%-0.32%35.53%41.59%77.10%32.29%--31.21%-40.35%-65.30%-72.17%56.52%

Earnings

Report DateOct 21, 2020Feb 24, 2021Apr 27, 2021Aug 24, 2021Oct 27, 2021Dec 31, 2021Apr 1, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Apr 20, 2023Aug 14, 2023
EPS Estimate------------
EPS Actual0.360.200.290.260.250.060.060.170.09-0.010.080.11
Surprise------------
TimingPre-marketAfter-hoursPre-marketAfter-hoursPre-market-Pre-market---Pre-marketPre-market

Key Statistics & Ratios

Market Cap2.10B
Enterprise Value1.82B
Trailing P/E0.00
Forward P/E0.00
Price / Sales5.89
Price / Book1.85
EPS-0.36
Book Value18.57
Revenue (TTM)356.56M
Gross Profit (TTM)224.07M
EBITDA-8.33M
Profit Margin-9.47%
Operating Margin0.56%
Return on Equity-3.12%
Return on Assets-2.36%
Shares Outstanding93.57M
Shares Float56.16M
Beta0.49
Dividend Yield0.45%
Dividend Rate0.10
Payout Ratio750.00%

Dividends

20261×
0.10Jun 3, 2026
20251×
0.10May 29, 2025
20241×
0.15May 29, 2024
20231×
0.14May 25, 2023
20221×
0.27May 18, 2022
20211×
0.28May 28, 2021